These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34090207)

  • 1. The X-ray structure of tubulysin analogue TGL in complex with tubulin and three possible routes for the development of next-generation tubulysin analogues.
    Li W; Tan L; Zhang Z; Xia Q; Lei D; Li Y; Zhang T; Zeng S; Sima X; Wang Y
    Biochem Biophys Res Commun; 2021 Aug; 565():29-35. PubMed ID: 34090207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
    Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
    FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insights into Structure-Activity Relationships, and Tubulysin-Tubulin Binding Derived from X-ray Crystallographic Analysis.
    Nicolaou KC; Pan S; Pulukuri KK; Ye Q; Rigol S; Erande RD; Vourloumis D; Nocek BP; Munneke S; Lyssikatos J; Valdiosera A; Gu C; Lin B; Sarvaiaya H; Trinidad J; Sandoval J; Lee C; Hammond M; Aujay M; Taylor N; Pysz M; Purcell JW; Gavrilyuk J
    J Org Chem; 2021 Feb; 86(4):3377-3421. PubMed ID: 33544599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules.
    Wang Y; Benz FW; Wu Y; Wang Q; Chen Y; Chen X; Li H; Zhang Y; Zhang R; Yang J
    Mol Pharmacol; 2016 Feb; 89(2):233-42. PubMed ID: 26660762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
    Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
    Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.
    Leverett CA; Sukuru SC; Vetelino BC; Musto S; Parris K; Pandit J; Loganzo F; Varghese AH; Bai G; Liu B; Liu D; Hudson S; Doppalapudi VR; Stock J; O'Donnell CJ; Subramanyam C
    ACS Med Chem Lett; 2016 Nov; 7(11):999-1004. PubMed ID: 27882198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy.
    Cao S; Dong YH; Wang DF; Liu ZP
    Curr Med Chem; 2020; 27(27):4567-4576. PubMed ID: 32175831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
    Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
    Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging the maytansine and vinca sites: Cryptophycins target β-tubulin's T5-loop.
    Abel AC; Mühlethaler T; Dessin C; Schachtsiek T; Sammet B; Sharpe T; Steinmetz MO; Sewald N; Prota AE
    J Biol Chem; 2024 Jun; 300(6):107363. PubMed ID: 38735475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
    Sáez-Calvo G; Sharma A; Balaguer FA; Barasoain I; Rodríguez-Salarichs J; Olieric N; Muñoz-Hernández H; Berbís MÁ; Wendeborn S; Peñalva MA; Matesanz R; Canales Á; Prota AE; Jímenez-Barbero J; Andreu JM; Lamberth C; Steinmetz MO; Díaz JF
    Cell Chem Biol; 2017 Jun; 24(6):737-750.e6. PubMed ID: 28579361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of tubulysin analogues.
    Courter JR; Hamilton JZ; Hendrick NR; Zaval M; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127241. PubMed ID: 32527543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total synthesis and biological evaluation of tubulysin U, tubulysin V, and their analogues.
    Balasubramanian R; Raghavan B; Begaye A; Sackett DL; Fecik RA
    J Med Chem; 2009 Jan; 52(2):238-40. PubMed ID: 19102699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insight into the inhibition of tubulin by vinca domain peptide ligands.
    Cormier A; Marchand M; Ravelli RB; Knossow M; Gigant B
    EMBO Rep; 2008 Nov; 9(11):1101-6. PubMed ID: 18787557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The binding of vinca domain agents to tubulin: structural and biochemical studies.
    Cormier A; Knossow M; Wang C; Gigant B
    Methods Cell Biol; 2010; 95():373-90. PubMed ID: 20466145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug design.
    Zhang Z; Wang C; Ma L; Jiang X; Wu C; Wang Y; Jiang Y; Zheng W; Yang Y; Ma Y; Yang J
    Biochem Biophys Res Commun; 2019 Apr; 511(2):381-386. PubMed ID: 30803758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the synthesis of tubulysins.
    Xiangming X; Friestad GK; Lei Y
    Mini Rev Med Chem; 2013 Oct; 13(11):1572-8. PubMed ID: 23746060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR
    Burke PJ; Hamilton JZ; Pires TA; Lai HWH; Leiske CI; Emmerton KK; Waight AB; Senter PD; Lyon RP; Jeffrey SC
    Mol Cancer Ther; 2018 Aug; 17(8):1752-1760. PubMed ID: 29866744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship studies of novel tubulysin U analogues--effect on cytotoxicity of structural variations in the tubuvaline fragment.
    Shankar SP; Jagodzinska M; Malpezzi L; Lazzari P; Manca I; Greig IR; Sani M; Zanda M
    Org Biomol Chem; 2013 Apr; 11(14):2273-87. PubMed ID: 23411563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying drug-tubulin interactions by X-ray crystallography.
    Dorleans A; Knossow M; Gigant B
    Methods Mol Med; 2007; 137():235-43. PubMed ID: 18085233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.